Callos Andrew 4

What Happened
Andrew Callos, EVP & Chief Commercial Officer of Cytokinetics (CYTK), exercised 886 stock options on Feb 2, 2026 at an exercise price of $37.63 (total cost $33,340) and sold the same 886 shares the same day in an open-market sale at $62.10 per share, generating proceeds of $55,021 (gross difference $21,681). The Form 4 also records a derivative disposition entry related to the exercise.

Key Details

• Transaction date: 2026-02-02.
• Exercise: 886 shares at $37.63 each — total cost $33,340 (reported as acquisition, code M).
• Sale: 886 shares at $62.10 each — proceeds $55,021 (open market sale, code S).
• Derivative entry: 886 units disposed at $0 (code M) — related to the option exercise/settlement.
• Shares owned after the transaction: Not specified in this filing.
• Filing date: 2026-02-02 for transactions on the same date — no late filing indicated.
• Footnote: The option vests over 4 years with equal monthly installments (100% vested after four years).

Context
Because the exercise and the sale occurred on the same date for the same number of shares, this was an exercise of options followed immediately by an open-market sale of the acquired shares (often done to cover exercise costs and tax obligations). This type of transaction realizes a cash gain for the insider but does not, by itself, indicate a change in long-term conviction.